Price alert —
Sign in to get a one-time email the moment XNCR crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · XNCR
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -2854.7% | -1724.1% |
| 2025-12-31 | $0.0B | $-0.0B | $-0.1B | $-0.1B | -23.6% | -189.9% |
| 2025-09-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -28.7% | -226.3% |
| 2025-06-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -70.7% | -76.1% |
| 2025-03-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -147.9% | -131.9% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare XNCR vs peers
Line XNCR up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with XNCR
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-06 | -1.71 | -0.75 | -129.0% | -5.4% |
| 2026-02-25 | -0.09 | -0.58 | +84.6% | +13.1% |
| 2025-11-05 | -0.08 | -0.70 | +88.7% | -2.6% |
| 2025-08-06 | -0.41 | -0.71 | +42.6% | -2.3% |
| 2025-05-07 | -0.66 | -0.58 | -13.6% | +10.1% |
| 2025-02-27 | -0.62 | -0.79 | +21.1% | +2.5% |
| 2024-11-06 | -0.71 | -1.02 | +30.4% | +2.2% |
| 2024-08-05 | -1.07 | -0.79 | -35.8% | +0.4% |
| 2024-05-09 | -1.11 | -0.77 | -44.4% | -4.5% |
| 2024-02-27 | -0.31 | -0.35 | +12.4% | -14.1% |
| 2023-11-07 | -0.40 | -0.71 | +43.9% | -7.0% |
| 2023-08-03 | -0.37 | -0.81 | +54.2% | +3.5% |
| 2023-05-08 | -1.02 | -0.63 | -60.8% | -1.9% |
| 2023-02-23 | -0.20 | -0.81 | +75.4% | -3.1% |
| 2022-11-07 | -0.55 | -0.72 | +23.4% | +8.8% |
| 2022-08-03 | -0.57 | -0.47 | -21.3% | +0.3% |
| 2022-05-05 | 0.39 | -0.45 | +186.2% | +4.1% |
| 2022-02-23 | 1.21 | -0.32 | +481.1% | +3.2% |
| 2021-11-08 | -0.69 | -0.70 | +2.1% | -5.4% |
| 2021-08-04 | 0.87 | -0.55 | +257.4% | +3.9% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| XNCR ★ | $1B | — | -4.9 | 13.3 | -5.1 | 2.0 | -152.2% | -86.2% | — | -5.94% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 77.91%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 13,035,918 | 17.58% |
| Primecap Management Company | 10,338,022 | 13.94% |
| BVF Inc. | 7,133,720 | 9.62% |
| RTW Investments LP | 6,777,461 | 9.14% |
| RA Capital Management, L.P. | 4,897,237 | 6.61% |
| State Street Corporation | 4,352,036 | 5.87% |
| Vanguard Portfolio Management LLC | 3,500,342 | 4.72% |
| Vanguard Capital Management LLC | 3,101,647 | 4.18% |
| TCG Crossover Management, LLC | 2,452,138 | 3.31% |
| EcoR1 Capital, LLC | 2,183,000 | 2.94% |
Insider activity · 90d
14 buys / 1 sells · ratio 14.0 · Finnhub
- Feigal Ellen SELL 12,340 @ $13.06
- Deshaies Raymond Joseph BUY 20,604
- Deshaies Raymond Joseph BUY 10,302
- Feigal Ellen BUY 20,604
- Feigal Ellen BUY 22,642
- Klencke Barbara BUY 20,604
- Klencke Barbara BUY 29,974
- GUSTAFSON KURT A BUY 20,604
- GUSTAFSON KURT A BUY 25,011
- Montgomery Alan Bruce BUY 20,604
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-08 | FORM 4 | view · |
| 4 | 2026-07-08 | FORM 4 | view · |
| 4 | 2026-07-08 | FORM 4 | view · |
| 4 | 2026-07-08 | FORM 4 | view · |
| 4 | 2026-07-08 | FORM 4 | view · |
| 4 | 2026-07-08 | FORM 4 | view · |
| 4 | 2026-07-08 | FORM 4 | view · |
| 4 | 2026-07-08 | FORM 4 | view · |
| 4 | 2026-06-22 | FORM 4 | view · |
| 8-K | 2026-06-18 | 8-K | view · |
| 4 | 2026-06-17 | FORM 4 | view · |
| 4 | 2026-06-17 | FORM 4 | view · |
| 4 | 2026-06-17 | FORM 4 | view · |
| 4 | 2026-06-17 | FORM 4 | view · |
| 10-Q | 2026-05-06 | 10-Q | view · |
| 8-K | 2026-05-06 | 8-K | view · |
| 8-K | 2026-05-05 | 8-K | view · |
| DEF 14A | 2026-04-27 | DEF 14A | view · |
| 8-K | 2026-04-27 | 8-K | view · |
| 4 | 2026-04-13 | FORM 4 | view · |
| 4 | 2026-03-09 | FORM 4 | view · |
| 4 | 2026-03-09 | FORM 4 | view · |
| 4 | 2026-03-09 | FORM 4 | view · |
| 4 | 2026-03-09 | FORM 4 | view · |
| 8-K | 2026-03-09 | 8-K | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 8-K | 2026-03-04 | 8-K | view · |
| 10-K | 2026-02-25 | 10-K | view · |
| 8-K | 2026-02-25 | 8-K | view · |
| 4 | 2026-01-26 | FORM 4 | view · |
| 8-K | 2026-01-08 | 8-K | view · |
| 4 | 2025-12-23 | FORM 4 | view · |
| 4 | 2025-12-23 | FORM 4 | view · |
| 10-Q | 2025-11-05 | 10-Q | view · |
| 8-K | 2025-11-05 | 8-K | view · |
| 8-K | 2025-10-24 | 8-K | view · |
| 10-Q | 2025-08-06 | 10-Q | view · |
| 8-K | 2025-08-06 | 8-K | view · |
| 4 | 2025-07-31 | FORM 4 | view · |
| 8-K | 2025-07-31 | 8-K | view · |
| 4 | 2025-06-16 | PRIMARY DOCUMENT | view · |
| 4 | 2025-06-16 | PRIMARY DOCUMENT | view · |
| 4 | 2025-06-16 | PRIMARY DOCUMENT | view · |
| 4 | 2025-06-16 | PRIMARY DOCUMENT | view · |
| 4 | 2025-06-16 | PRIMARY DOCUMENT | view · |
| 4 | 2025-06-16 | PRIMARY DOCUMENT | view · |
| 4 | 2025-06-16 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-06-13 | 8-K | view · |
| 10-Q | 2025-05-07 | 10-Q | view · |
| 8-K | 2025-05-07 | 8-K | view · |
| 4 | 2025-05-06 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-04-30 | 8-K | view · |
| DEF 14A | 2025-04-23 | DEF 14A | view · |
| 4 | 2025-04-14 | PRIMARY DOCUMENT | view · |
| 4 | 2025-03-13 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-03-13 | 8-K | view · |
| 4 | 2025-03-11 | PRIMARY DOCUMENT | view · |
About XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to …
Options picks · XNCR
ITM + OTM ideas from the latest scanLoading…
Congress trades · XNCR
STOCK Act disclosuresLoading…
SEC filings & insiders · XNCR
EDGAR · liveLoading…
Holders · XNCR
Institutions & insider activityLoading…